Cogent Biosciences (COGT) Competitors $32.67 +0.09 (+0.28%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$32.66 -0.02 (-0.05%) As of 05/22/2026 05:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock COGT vs. ROIV, MRNA, VTRS, GMAB, and ASNDShould you buy Cogent Biosciences stock or one of its competitors? MarketBeat compares Cogent Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cogent Biosciences include Roivant Sciences (ROIV), Moderna (MRNA), Viatris (VTRS), Genmab A/S (GMAB), and Ascendis Pharma A/S (ASND). These companies are all part of the "pharmaceutical products" industry. COGT vs. ROIVCOGT vs. MRNACOGT vs. VTRSCOGT vs. GMABCOGT vs. ASNDHow does Cogent Biosciences compare to Roivant Sciences?Roivant Sciences (NASDAQ:ROIV) and Cogent Biosciences (NASDAQ:COGT) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, earnings, risk, analyst recommendations and media sentiment. Do insiders & institutionals believe in ROIV or COGT? 64.8% of Roivant Sciences shares are held by institutional investors. 10.8% of Roivant Sciences shares are held by company insiders. Comparatively, 7.3% of Cogent Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is ROIV or COGT more profitable? Cogent Biosciences has a net margin of 0.00% compared to Roivant Sciences' net margin of -3,629.19%. Roivant Sciences' return on equity of -20.54% beat Cogent Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Roivant Sciences-3,629.19% -20.54% -19.43% Cogent Biosciences N/A -104.27%-54.64% Does the media favor ROIV or COGT? In the previous week, Roivant Sciences had 24 more articles in the media than Cogent Biosciences. MarketBeat recorded 24 mentions for Roivant Sciences and 0 mentions for Cogent Biosciences. Roivant Sciences' average media sentiment score of 0.33 beat Cogent Biosciences' score of 0.00 indicating that Roivant Sciences is being referred to more favorably in the media. Company Overall Sentiment Roivant Sciences Neutral Cogent Biosciences Neutral Which has more risk and volatility, ROIV or COGT? Roivant Sciences has a beta of 1.14, suggesting that its stock price is 14% more volatile than the broader market. Comparatively, Cogent Biosciences has a beta of 0.37, suggesting that its stock price is 63% less volatile than the broader market. Do analysts recommend ROIV or COGT? Roivant Sciences currently has a consensus price target of $33.05, indicating a potential upside of 10.30%. Cogent Biosciences has a consensus price target of $43.73, indicating a potential upside of 33.85%. Given Cogent Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Cogent Biosciences is more favorable than Roivant Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Roivant Sciences 1 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.75Cogent Biosciences 1 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 2.86 Which has stronger valuation & earnings, ROIV or COGT? Roivant Sciences has higher revenue and earnings than Cogent Biosciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRoivant Sciences$8.26M2,595.93-$171.98M-$0.60N/ACogent BiosciencesN/AN/A-$328.94M-$2.17N/A SummaryRoivant Sciences beats Cogent Biosciences on 11 of the 16 factors compared between the two stocks.How does Cogent Biosciences compare to Moderna?Cogent Biosciences (NASDAQ:COGT) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, analyst recommendations, institutional ownership, profitability, valuation and risk. Which has higher valuation and earnings, COGT or MRNA? Cogent Biosciences has higher earnings, but lower revenue than Moderna. Cogent Biosciences is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCogent BiosciencesN/AN/A-$328.94M-$2.17N/AModerna$1.94B9.57-$2.82B-$8.15N/A Do insiders and institutionals hold more shares of COGT or MRNA? 75.3% of Moderna shares are held by institutional investors. 7.3% of Cogent Biosciences shares are held by company insiders. Comparatively, 10.8% of Moderna shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has more risk and volatility, COGT or MRNA? Cogent Biosciences has a beta of 0.37, suggesting that its stock price is 63% less volatile than the broader market. Comparatively, Moderna has a beta of 1.05, suggesting that its stock price is 5% more volatile than the broader market. Does the media prefer COGT or MRNA? In the previous week, Moderna had 17 more articles in the media than Cogent Biosciences. MarketBeat recorded 17 mentions for Moderna and 0 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 0.00 beat Moderna's score of -0.19 indicating that Cogent Biosciences is being referred to more favorably in the media. Company Overall Sentiment Cogent Biosciences Neutral Moderna Neutral Is COGT or MRNA more profitable? Cogent Biosciences has a net margin of 0.00% compared to Moderna's net margin of -143.55%. Moderna's return on equity of -26.64% beat Cogent Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Cogent BiosciencesN/A -104.27% -54.64% Moderna -143.55%-26.64%-19.32% Do analysts rate COGT or MRNA? Cogent Biosciences presently has a consensus price target of $43.73, suggesting a potential upside of 33.85%. Moderna has a consensus price target of $35.73, suggesting a potential downside of 23.78%. Given Cogent Biosciences' stronger consensus rating and higher probable upside, equities research analysts clearly believe Cogent Biosciences is more favorable than Moderna.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cogent Biosciences 1 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 2.86Moderna 5 Sell rating(s) 12 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 1.84 SummaryCogent Biosciences and Moderna tied by winning 8 of the 16 factors compared between the two stocks.How does Cogent Biosciences compare to Viatris?Cogent Biosciences (NASDAQ:COGT) and Viatris (NASDAQ:VTRS) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, media sentiment, risk and analyst recommendations. Do insiders & institutionals believe in COGT or VTRS? 79.9% of Viatris shares are held by institutional investors. 7.3% of Cogent Biosciences shares are held by company insiders. Comparatively, 0.3% of Viatris shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has stronger valuation and earnings, COGT or VTRS? Cogent Biosciences has higher earnings, but lower revenue than Viatris. Viatris is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCogent BiosciencesN/AN/A-$328.94M-$2.17N/AViatris$14.56B1.33-$3.51B-$0.26N/A Do analysts rate COGT or VTRS? Cogent Biosciences currently has a consensus target price of $43.73, indicating a potential upside of 33.85%. Viatris has a consensus target price of $16.43, indicating a potential downside of 1.33%. Given Cogent Biosciences' stronger consensus rating and higher probable upside, research analysts clearly believe Cogent Biosciences is more favorable than Viatris.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cogent Biosciences 1 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 2.86Viatris 1 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.38 Which has more risk & volatility, COGT or VTRS? Cogent Biosciences has a beta of 0.37, suggesting that its share price is 63% less volatile than the broader market. Comparatively, Viatris has a beta of 0.88, suggesting that its share price is 12% less volatile than the broader market. Does the media prefer COGT or VTRS? In the previous week, Viatris had 3 more articles in the media than Cogent Biosciences. MarketBeat recorded 3 mentions for Viatris and 0 mentions for Cogent Biosciences. Viatris' average media sentiment score of 0.04 beat Cogent Biosciences' score of 0.00 indicating that Viatris is being referred to more favorably in the news media. Company Overall Sentiment Cogent Biosciences Neutral Viatris Neutral Is COGT or VTRS more profitable? Cogent Biosciences has a net margin of 0.00% compared to Viatris' net margin of -2.04%. Viatris' return on equity of 19.04% beat Cogent Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Cogent BiosciencesN/A -104.27% -54.64% Viatris -2.04%19.04%7.62% SummaryCogent Biosciences and Viatris tied by winning 8 of the 16 factors compared between the two stocks.How does Cogent Biosciences compare to Genmab A/S?Genmab A/S (NASDAQ:GMAB) and Cogent Biosciences (NASDAQ:COGT) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and risk. Does the media prefer GMAB or COGT? In the previous week, Genmab A/S had 2 more articles in the media than Cogent Biosciences. MarketBeat recorded 2 mentions for Genmab A/S and 0 mentions for Cogent Biosciences. Genmab A/S's average media sentiment score of 0.30 beat Cogent Biosciences' score of 0.00 indicating that Genmab A/S is being referred to more favorably in the media. Company Overall Sentiment Genmab A/S Neutral Cogent Biosciences Neutral Do institutionals and insiders hold more shares of GMAB or COGT? 7.1% of Genmab A/S shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by insiders. Comparatively, 7.3% of Cogent Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is GMAB or COGT more profitable? Genmab A/S has a net margin of 21.05% compared to Cogent Biosciences' net margin of 0.00%. Genmab A/S's return on equity of 15.34% beat Cogent Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Genmab A/S21.05% 15.34% 8.94% Cogent Biosciences N/A -104.27%-54.64% Which has better valuation & earnings, GMAB or COGT? Genmab A/S has higher revenue and earnings than Cogent Biosciences. Cogent Biosciences is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGenmab A/S$3.90B4.29$963M$1.3220.36Cogent BiosciencesN/AN/A-$328.94M-$2.17N/A Do analysts rate GMAB or COGT? Genmab A/S presently has a consensus price target of $39.07, suggesting a potential upside of 45.41%. Cogent Biosciences has a consensus price target of $43.73, suggesting a potential upside of 33.85%. Given Genmab A/S's higher possible upside, research analysts clearly believe Genmab A/S is more favorable than Cogent Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genmab A/S 1 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 2.83Cogent Biosciences 1 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 2.86 Which has more volatility & risk, GMAB or COGT? Genmab A/S has a beta of 0.86, suggesting that its stock price is 14% less volatile than the broader market. Comparatively, Cogent Biosciences has a beta of 0.37, suggesting that its stock price is 63% less volatile than the broader market. SummaryGenmab A/S beats Cogent Biosciences on 12 of the 15 factors compared between the two stocks.How does Cogent Biosciences compare to Ascendis Pharma A/S?Ascendis Pharma A/S (NASDAQ:ASND) and Cogent Biosciences (NASDAQ:COGT) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, analyst recommendations, valuation, earnings and risk. Which has more volatility & risk, ASND or COGT? Ascendis Pharma A/S has a beta of 0.41, suggesting that its share price is 59% less volatile than the broader market. Comparatively, Cogent Biosciences has a beta of 0.37, suggesting that its share price is 63% less volatile than the broader market. Does the media favor ASND or COGT? In the previous week, Ascendis Pharma A/S had 4 more articles in the media than Cogent Biosciences. MarketBeat recorded 4 mentions for Ascendis Pharma A/S and 0 mentions for Cogent Biosciences. Ascendis Pharma A/S's average media sentiment score of 0.50 beat Cogent Biosciences' score of 0.00 indicating that Ascendis Pharma A/S is being referred to more favorably in the media. Company Overall Sentiment Ascendis Pharma A/S Positive Cogent Biosciences Neutral Is ASND or COGT more profitable? Ascendis Pharma A/S has a net margin of 57.87% compared to Cogent Biosciences' net margin of 0.00%. Ascendis Pharma A/S's return on equity of 0.00% beat Cogent Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Ascendis Pharma A/S57.87% N/A -8.37% Cogent Biosciences N/A -104.27%-54.64% Which has preferable valuation & earnings, ASND or COGT? Ascendis Pharma A/S has higher revenue and earnings than Cogent Biosciences. Cogent Biosciences is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAscendis Pharma A/S$814.57M18.92-$258M$8.6728.49Cogent BiosciencesN/AN/A-$328.94M-$2.17N/A Do analysts recommend ASND or COGT? Ascendis Pharma A/S presently has a consensus target price of $295.39, suggesting a potential upside of 19.57%. Cogent Biosciences has a consensus target price of $43.73, suggesting a potential upside of 33.85%. Given Cogent Biosciences' higher probable upside, analysts plainly believe Cogent Biosciences is more favorable than Ascendis Pharma A/S.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ascendis Pharma A/S 1 Sell rating(s) 0 Hold rating(s) 16 Buy rating(s) 2 Strong Buy rating(s) 3.00Cogent Biosciences 1 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 2.86 SummaryAscendis Pharma A/S beats Cogent Biosciences on 12 of the 13 factors compared between the two stocks. Get Cogent Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for COGT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding COGT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart COGT vs. The Competition ExportMetricCogent BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.58B$3.38B$6.44B$12.33BDividend YieldN/A2.26%2.76%5.28%P/E Ratio-15.0618.9321.2825.67Price / SalesN/A320.52553.3782.73Price / CashN/A125.9643.6856.73Price / Book10.277.1110.367.14Net Income-$328.94M$24.45M$3.56B$335.80M7 Day Performance-0.03%3.32%5.12%3.02%1 Month Performance-11.25%2.52%3.54%2.48%1 Year Performance577.80%63.09%34.14%35.08% Cogent Biosciences Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)COGTCogent Biosciences2.2947 of 5 stars$32.67+0.3%$43.73+33.8%+577.8%$5.58BN/AN/A80ROIVRoivant Sciences2.2555 of 5 stars$28.55-2.5%$30.55+7.0%+175.6%$20.96B$13.31MN/A860News CoverageEarnings ReportAnalyst ForecastInsider TradeOptions VolumeHigh Trading VolumeMRNAModerna1.2803 of 5 stars$48.11-1.9%$35.73-25.7%+78.5%$19.46B$1.94BN/A4,700Trending NewsInsider TradeVTRSViatris2.1982 of 5 stars$16.50+0.1%$15.71-4.8%+100.8%$19.19B$14.30BN/A30,000Analyst ForecastGMABGenmab A/S4.1647 of 5 stars$26.37-0.6%$39.07+48.2%+29.1%$16.55B$3.72B19.983,029 Related Companies and Tools Related Companies Roivant Sciences Alternatives Moderna Alternatives Viatris Alternatives Genmab A/S Alternatives Ascendis Pharma A/S Alternatives Regencell Bioscience Alternatives Summit Therapeutics Alternatives BridgeBio Pharma Alternatives Axsome Therapeutics Alternatives Dr. Reddy's Laboratories Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:COGT) was last updated on 5/24/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredYour computer is about to become a museum pieceFuturist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...Eagle Publishing | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredJune 12: Elon Musk’s “Day-One Retirement Plan.”SpaceX is expected to go public on June 12 - and for the first time, everyday investors may have a way in befo...Brownstone Research | SponsoredOne page of the SpaceX S-1 will move this stock overnightWhen SpaceX files its S-1 in June, the SEC will require full disclosure of operating expenses - including powe...Behind the Markets | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cogent Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cogent Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
